Renier J Brentjens

This inventor holds 22 USPTO granted patents and 24 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Immunotherapy Techniques. Top assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Renier J Brentjens. Retrieved from https://idiyas.com/inventor/renier-j-brentjens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 24)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 19)

EPO Patents = 5 (Patent Applications = 25)

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 53(Granted Patents)

Location History:

Short Hills, NJ (US) (2018 - 2021)
New York, NY (US) (2020 - 2024)

Company Filing History:

21 out of 621

Memorial Sloan Kettering Cancer Center

patents

18 out of 52

Eureka Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Antibodies

Chimeric Antigen Receptors

G-Protein Coupled Receptor

B-Cell Maturation Antigen

Fc Receptor-Like 5

Nucleic Acid Molecules

IL-36

Immunoresponsive Cells

PD-1

Immunotherapy

Methods of Use

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655211 - ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USE (2026-06-16),

2. 12636375 - Antibodies targeting Fc receptor-like 5 and methods of use (2026-05-26),

3. 12544440 - IL-36 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF (2026-02-10),

4. 12139538 - Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof (2024-11-12),

5. 11866478 - Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor (2024-01-09),

6. 11820806 - Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof (2023-11-21),

7. 11766474 - IL-36 secreting immunoresponsive cells and uses thereof (2023-09-26),

8. 11725059 - Antibodies targeting B-cell maturation antigen and methods of use (2023-08-15),

9. 11566071 - Nucleic acid molecules encoding anti-GPRC5D antibodies (2023-01-31),

10. 11136392 - PD-1 immune modulating agents (2021-10-05),

11. 11103531 - Compositions and methods for immunotherapy (2021-08-31),

12. 11059891 - Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof (2021-07-13),

13. 11000549 - Methods of using chimeric antigen receptors targeting B-cell maturation antigen and uses thereof (2021-05-11),

14. 10947314 - Antibodies targeting b-cell maturation antigen and methods of use (2021-03-16),

15. 10918665 - Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof (2021-02-16),

Title: Innovator Spotlight: Renier J Brentjens - Pioneering Cancer Treatment Advancements

Introduction:

Renier J Brentjens is a distinguished inventor based in New York, NY, with a remarkable portfolio of 18 patents to his name. His groundbreaking work in the field of chimeric antigen receptors (CARs) has significantly advanced the treatment of multiple myeloma, showcasing his dedication to revolutionizing cancer therapy.

Latest Patents:

Renier J Brentjens' latest patents focus on developing nucleic acid molecules encoding CARs that target G-protein coupled receptors, specifically GPRC5D. These CARs exhibit enhanced immune-activating properties and demonstrate potent anti-tumor activity. The innovative methods and compositions detailed in his patents offer new avenues for effectively treating multiple myeloma.

Career Highlights:

Renier J Brentjens has made significant contributions to the field of oncology through his work at renowned institutions like the Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. His expertise in CAR technologies has paved the way for novel therapeutic approaches that hold promise in combating cancer and improving patient outcomes.

Collaborations:

Throughout his career, Renier J Brentjens has collaborated with esteemed professionals in the industry, including Cheng Liu and Eric L Smith. These collaborations have enriched his research endeavors and led to the development of cutting-edge solutions for challenging medical conditions.

Conclusion:

Renier J Brentjens' relentless pursuit of innovation in cancer immunotherapy has positioned him as a trailblazer in the field. His transformative work continues to impact the lives of patients battling cancer, highlighting the profound significance of his contributions to the medical community.

Profile summary based on public USPTO records.